Although peroxisome proliferator-activated receptor gamma (PPAR␥) agonists such as thiazolidinediones (TZDs) are widely used to treat type 2 diabetes, how its activation in individual tissues contributes to TZD's therapeutic action remains controversial. As TZDs are known to have receptor-independent effects, we sought to establish gain-offunction animal models to delineate the receptor's insulin-sensitizing actions. Unexpectedly, we find that selective activation of PPAR␥ in adipocytes, but not in macrophages, is sufficient for whole-body insulin sensitization equivalent to systemic TZD treatment. In addition to improved adipokine, inflammatory, and lipid profiles, PPAR␥ activation in mature adipocytes normalizes serum insulin without increased adipogenesis. Co-culture studies indicated that PPAR␥-activated adipocytes broadly suppress induction of inflammatory cytokines and C-X-C family chemokines in macrophages. Collectively, these data describe an ''adipocentric'' model in which adipose activation of PPAR␥ is sufficient for complete insulin sensitization and suggest a specific application for fat selective PPAR␥ modulators in diabetic therapy.
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inflammation ͉ insulin signaling ͉ metabolic syndrome ͉ nuclear hormone receptors I t is increasingly recognized that adipose tissue is an active metabolic and endocrine organ that impacts widely on wholebody homeostasis. One key factor in supporting the centrality of adipose tissue in whole-body glucose metabolism is PPAR␥, a nuclear receptor that is critical both for adipocyte differentiation and for maintenance of mature adipocytes (1, 2) . PPAR␥ was shown to be critical both for adipocyte differentiation and for maintenance of mature adipocytes (1, 3) . Thiazolidinediones (TZDs), the only class of insulin-sensitizing drugs in clinical use, are high-affinity ligands for PPAR␥ (2, 4, 5) . Two currently available TZDs, rosiglitazone and pioglitazone, are widely prescribed antidiabetic drugs. Although PPAR␥ is predominantly expressed in adipose tissue (2) , major tissues of insulin-responsive glucose homeostasis include skeletal muscle and liver. While the complete lack of PPAR␥ leads to embryonic lethality (6) , previous studies that involve tissue specific deletion of PPAR␥ have been confusing. Adipose-specific mouse knockouts of PPAR␥, when fed a high-fat diet, develop systemic insulin resistance (7, 8) . Lack of PPAR␥ in muscle, on the other hand, leads to muscle insulin resistance under a normal chow diet (9, 10) . In addition, it was recently reported that macrophage-specific deletion of PPAR␥ results in systemic insulin resistance and glucose intolerance (11, 12) . While these findings point to the contribution of adipose and non-adipose PPAR␥ in the origin of insulin resistance, use of knockout models fails to address how and where TZDs act to promote insulin sensitization in diabetic conditions, and whether the cellular targets of insulin sensitivity are the same or different from those promoting insulin resistance. Moreover, it has been demonstrated that absence of adipose PPAR␥ can be compensated by increased gene expression in liver (13) and muscle (14) . To circumvent such complications caused by the loss-of-function, we generated gain-of-function PPAR␥ models to investigate the role of the receptor in dietinduced insulin resistance. Surprisingly, PPAR␥ activation in adipocytes was sufficient to improve whole-body insulin sensitivity to a degree similar to systemic TZD treatment. In addition to improved adipokine profiles and reduced serum lipids, adipose PPAR␥ activation suppressed high fat diet-induced inflammation and dramatically lowered circulating insulin levels.
Results

Adipose-Specific Activation of PPAR␥ Increases Whole-Body Insulin
Sensitivity. To address the selective role of adipose in insulin sensitization, transgenic mice were generated expressing a VP16-PPAR␥ fusion protein (VP␥) under the control of the aP2 promoter. VP␥ has been shown to regulate PPAR␥ target genes independent of ligand, and has no activity on response elements for other nuclear receptors (15) . In vitro, VP␥ efficiently up-regulated a PPAR response element (PPRE) driven reporter in the absence of ligand (Fig. S1 A) . The resulting transgenic (TG) mice were found to express a level of the transgene similar to that of endogenous levels of PPAR␥ in white (WAT) and brown (BAT) adipose tissues; no significant expression was detected in other tissues (Fig. S1B) . While TZDs can promote increased adipogenesis and weight gain, the late adipogenic stage expression of the aP2 promoter restricts the transgene activity to nonproliferating mature adipocytes (Fig. S1C) . Thus, this strategy allows us to selectively address the impact of a single cell type, (i.e., the mature adipocyte) to insulin sensitization. By Western blot, VP␥ band was detected in adipose tissue from TG but not wild-type (WT) animals (Fig. S1E) .
Under normal chow, TG mice exhibited apparently normal growth and development of epididymal, perirenal, subcutaneous, and brown adipose tissues, unaltered glucose excursion curves and similar circulating lipids (Table S1 and Figs. S1F and S2 A and B). This correlates with the observed lack of effect of TZDs in insulin sensitive lean subjects (16) . To study the effects of adipose-specific PPAR␥ activation in the context of insulin resistance, animals were fed high-fat diet (HFD) for 3 months. While the TG mice experienced a similar increase in WAT mass and weight, the TG cohort had lower fasting glucose levels compared to WT animals, indicating improved glucose metabolism (Table S1 ). Indeed, glucose tolerance (GTT) and insulin tolerance (ITT) tests revealed that TG mice display significantly diminished glucose excursions and en-hanced insulin sensitivity ( Fig. S1 G and H) . Compared to WT mice, insulin levels in TG mice were dramatically diminished more than 3.5-fold on HFD (3.6 vs. 0.98 ng/mL) (Fig. 1A) indicating that selective activation of PPAR␥ in adipocytes is protective against diet-induced insulin resistance.
Adipose PPAR␥ Activation Has a Comparable Effect to TZD Treatment.
These results prompted us to compare the therapeutic effect of TZD treatment with adipose-specific PPAR␥ activation in the insulin resistant state. Both WT and TG mice, fed HFD, were treated with or without pioglitazone. While TZD treatment resulted in a 9-23% increase in body weight due to enhanced adipose mass, TG groups did not show such an increase (Table 1) . Importantly, this shows that activation of PPAR␥ in mature adipocytes does not promote proliferation. Surprisingly, fasting glucose and insulin levels were reduced to the same degree in TZD-treated and TG groups ( Table 1) . As shown in Fig. 1 B and C, respectively, ITT and GTT indicated that both TZD-treated and transgenic animals have comparably improved insulin sensitivities and glucose tolerance compared to nontreated controls. WT mice exhibited hyperinsulinemia during GTT, while TZD-treated and TG groups had much lower levels of circulating insulin (Fig. 1D ), indicating that both TZD treatment and adipose PPAR␥ transgene expression produced robust protection against insulin resistance. Indeed, the homeostasis model assessment of insulin resistance (HOMA-IR), a product of basal insulin and glucose concentrations, pointed to similarly dramatic alleviation in insulin resistance by either TZD treatment or adipose restricted PPAR␥ activation (Fig. 1E) . Hyperinsulinemic-euglycemic clamp studies were performed to further delineate whole body and tissue-specific insulin sensitivity and glucose metabolism. The glucose infusion rates required to maintain euglycemia were dramatically increased in both TZD-treated and TG mice (Fig. 1F) , indicating equivalent states of systemic insulin sensitivity. Glucose disposal rates, which primarily occur through muscle, were enhanced in TZD and TG groups (Fig. 1G ). Three-month-old mice (n ϭ 9) were fed HFD for 6 months and treated with or without TZD (pioglitazone) for 2-3 months. For fasting parameters, blood was collected after fasting overnight and plasma was isolated. HFD, high fat diet; WAT, epididymal fat. *P Ͻ 0.05 against WT.
In addition, the ability of insulin to suppress hepatic glucose production during the clamp was significantly increased in TZD and TG animals ( Fig. 1 H and I) . As with the GIR, the GDR showed the greatest improvement in the TG cohort. Interestingly, TZD treatment did not further improve insulin sensitization in TG mice, raising the question as to whether direct action of TZDs in muscle or liver is necessary. Together, these results clearly demonstrate that adipose-restricted PPAR␥ activation is as effective as TZD treatment in reversing systemic insulin resistance. Consistent with the above observations, circulating free fatty acid, triglycerides, leptin, and RBP4 levels were significantly reduced in both TZD-treated and TG mice (Table 1 ). In contrast, levels of adiponectin and resistin significantly changed only with TZD treatment. Although diet-induced obesity is known to cause adipocyte hypertrophy and leukocyte infiltration in WAT (17) (18) (19) (20) , adipocytes from TG WAT were smaller in size and greater in number per unit area than those from either WT or TZD-treated WT WAT (Fig. 2A) . Similarly, brown adipocytes from TG mice were smaller and contained markedly less lipids (Fig. 2B ). In addition, both TZD treatment and adipose PPAR␥ activation led to a significant reduction in macrophage specific CD68-positive cells in WAT (Fig. 2C ) and a remarkable secondary improvement in hepatic steatosis in TG mice (Fig. S2C ). These improvements in adipocyte hypertrophy and inflammation emphasize that critical systemic benefits of TZDs can be achieved by selective activation of the adipocentric PPAR␥ gene network.
Adipose PPAR␥ Influences Lipid and Carbohydrate Metabolism, Insulin
Signaling, and Inflammatory Genes. As the VP␥ transgene and TZD treatment had similar but not identical effects, a comparison of their molecular targets may offer insights into the genetic mechanisms underlying insulin sensitization. We compared expression profiles in WAT from four HFD-fed cohorts, including WT, WTϩTZD, TG, and TGϩTZD mice. Fold change was calculated against the transcript levels of the WT group. The results from WAT revealed significantly altered expression in a large cluster of genes in TZDtreated and TG mice (Dataset S1). Among them, 1,080 transcripts were up-regulated and 723 down-regulated in all three groups (Fig.  3A) . Gene Ontology annotations of the combined 1,803 gene set showed significantly enriched functional categories, which include lipid and fatty acid metabolism, carboxylic acid and glucose metabolism, intracellular signaling, immune response, and lymphocyte activation (Fig. 3B) . Interestingly, the majority of ''immune system response'' genes showed down-regulation, while nearly all ''carboxylic acid metabolism'' genes were up-regulated (Fig. 3C ). In contrast, the ''lipid metabolic process'' category included a balance of both down-regulated (e.g., Rbp1, Apoa4, and Agpat4) and upregulated (e.g., Fabp4/aP2, Cd36, Scd1, Dgat1, and Pten) genes. Unexpectedly, several genes in the ''other'' category include components of the insulin signaling cascade such as Irs1, Irs2, Pi3k p85, and Glut4, all of which were significantly increased. In addition, liver ( Fig. S3A ) and muscle ( Fig. S3B) were examined in WT and TG groups. Although the numbers of gene changes were substantially smaller than those in WAT ( Fig. S3C and Dataset S2), a major gene category that was significantly enriched in these tissues is related to metabolism, inflammatory, and immune regulatory processes. These results prove that the constitutive adipose transgene is as effective as TZD treatment in activating and repressing target genes, and they identify a subset (red genes in Fig. 3A ) that closely track insulin sensitivity.
To complement the findings observed in the microarray analysis, real-time quantitative PCR (qPCR) was performed for several key factors in WAT (Fig. 4A ). PPAR␥ and established PPAR target genes such as aP2, lipoprotein lipase (LPL), PEPCK, CD36, and adipsin were all increased in TZD-treated or TG animals ( Fig. 4A and Fig. S4A ). Unexpectedly, there was no additive effect on these genes in TZD-treated TG mice. Enhanced expression of key factors playing roles in the insulin signaling pathway, including IRS1, IRS2, GLUT4, phosphatidylinositol 3-kinase (PI3K), and insulin receptor, but not Akt, was found in both TZD-treated and TG groups, supporting the microarray results (Fig. 4A) . Up-regulation of IRS1 and IRS2 was also confirmed by immunoblot analysis (Fig. S4B) . Inflammatory mediators TNF␣, MCP-1, and MIP1␣, and macrophage markers F4/80 and CD68 exhibited modest decreases in expression (Fig. S4A) . These results suggest that adipose PPAR␥ activation may act to limit the inflammatory response in this tissue.
PPAR␥ Activation in Adipocytes Controls Inflammatory Processes in
Macrophages. It was reported that aP2 is expressed in the macrophage and its expression enhanced by cell activation (21) . This finding leaves the possibility that the receptor can also be activated in macrophages in the TG mice and that insulin sensitization could be contributed by these cells. To investigate this possibility, stromal vascular fractions (SVF) and adipocytes (AC) were separated from adipose tissue, and the macrophage population (SVF-M) was enriched from SVF. A control experiment confirmed enrichment of an adipocyte marker in the AC and macrophage markers in the SVF-M (Fig. S5A) . The results showed that SVF-M had very little expression of the transgene, PPAR␥, or aP2 compared to AC when fed a normal diet or HFD (Fig. S5B) . To directly address the role of PPAR␥ in macrophages, we created an additional mouse model named ''mTG'' in which the transgene expression is driven under the control of a macrophage-specific CD68 promoter (22) . The transgene is selectively and highly expressed in bone marrowderived and peritoneal macrophages (Fig. S6A) . Among different tissues examined, adipose tissue was found to contain substantial macrophage-specific transgene expression (Fig. S6B) . In WAT from mTG mice, SVF-M, but not AC, exhibited induction of transgene, PPAR␥, and aP2 expression; HFD feeding increased their expression in SVF-M, indicating more infiltration of this cell type (Fig.  S6C) . Nevertheless, mTG mice had no significant difference in body weight, lipid profiles, fasting glucose, and glucose excursion curves when they were fed either a normal diet or HFD (Fig. S7 ). This suggests that activation of PPAR␥ in macrophages under dietinduced obesity does not improve whole body glucose metabolism. Collectively, although we do not exclude the notion that macrophages per se can play a role in systemic insulin sensitization, macrophage PPAR␥ is not expected to be a major contributor to the phenotype observed in our aP2-driven transgenic animals. To explore the mechanism at the cellular level as to how inflammatory genes are down-regulated in the TG mice, a coculture system was used to examine whether PPAR␥ activation in adipocytes modulates the inflammatory function of leukocytes. We found that lipopolysaccharide (LPS)-activated RAW264.7 macrophages suppress PPAR␥, its target genes such as aP2, and insulin signaling components including IRS1 and Glut4 in 3T3-L1 preadipocytes (Fig. S8A) . In contrast, stable expression of PPAR␥ in 3T3-L1 cells reciprocally suppresses expression of lipopolysaccharide (LPS)-induced inflammatory and chemokine factors, including IL-6, TNF␣ and MCP-1 in macrophages, which is further repressed by adipocyte differentiation (Fig. S8B) . Adipocytic PPAR␥ did not alter IL-4 induced inflammatory cytokines and chemokines. Among the genes that are significantly repressed by TZDs and the transgene in the microarray studies above include the C-X-C family of chemokines. qPCR indicated that CXCL2, CXCL10, and CXCL16 are dramatically repressed by PPAR␥ activated WAT in vivo (Fig. 4B ). This repression was further supported by the in vitro experiment that adipocytic PPAR␥ activation reduces LPS-mediated induction of CXCL2, CXCL10, and CXCL16 in macrophages (Fig. 4B) . Thus, adipocyte PPAR␥ itself is anti-inflammatory, counteracting mac- rophage infiltration and pro-inflammatory activities, presumably by the release of one or more secreted factors.
Adipocyte PPAR␥ Activation Modulates Insulin Signaling. Enhanced expression of important insulin signaling components in the experiments above prompted us to further investigate its key player, Akt (23) . Although Akt did not change at the transcriptional level (Fig.  4A) , basal phosphorylation of Akt on Ser-473, an indicator of Akt activation, is higher in WAT from both TZD-treated and TG mice and this enhanced Akt activity was further exaggerated during the insulin infusion (Fig. 4C) . Similarly, in muscle, Akt activation was enhanced in the presence of insulin in TG mice as well as TZDtreated WT mice. Taken together with the gene expression studies above, we conclude that either TZD treatment or transgenic PPAR␥ activation improves insulin sensitivity by increasing expression and posttranslational activation of key insulin signaling components in adipose tissue.
Adipose-Selective PPAR␥ Agonists May Be the Best Insulin Sensitizers.
Based on the results above, we hypothesized that compounds that act more effectively on adipose PPAR␥ than others should also confer greater insulin sensitizing effects. To test this hypothesis, we compared the physiological and gene expression effects of four PPAR␥ ligand treatments in Zucker fatty rats using the TZDs pioglitazone, rosiglitazone, troglitazone, and the non-TZD AG035029 (24) . As expected, each of the PPAR␥ ligand treatments improved the insulin sensitivity profiles of the rats compared to untreated controls (Table S2) . Insulin sensitization occurred with tissue-associated phenotypes, for example, improved GDR (muscle), HGP suppression (liver), and suppression of plasma FFAs (adipose tissue) during hyperinsulinemic euglycemic clamp studies. The PPAR␥ ligand treatments also resulted in significant gene expression changes in muscle, liver and adipose tissue ( Table 2) . Although each was insulin-sensitizing, the PPAR␥ ligands exhibited distinct physiology and gene expression altering efficacy profiles. For example, AG035029 was the most potent insulin sensitizer and the most efficient inducer of differential gene expression in adipose tissue. In contrast, troglitazone and rosiglitizone were most effective in altering liver and muscle genes. Thus, superior efficacy of AG035029 in adipose tissue is correlated with superior insulinsensitizing activity.
Discussion
In this report, we show that PPAR␥ activation in adipose tissue is sufficient to explain the body wide insulin-sensitizing actions of TZDs. Activation of PPAR␥ in adipocytes, but not in macrophages, leads to significant increases in glucose disposal rates in muscle and suppression of hepatic glucose production, and reverses systemic hyperglycemia and hyperinsulinemia. These results support our ''adipocentric'' model where fat is not only a contributor but a central player in diabetes-associated insulin sensitization. Two mechanisms have been proposed to explain how adipocytes contribute to the maintenance of whole body glucose homeostasis (2) . One is by the release of insulin-sensitizing adipose-derived hormones or adipokines, while the other is through the sequestering of excess fatty acids and triglycerides that induce insulin resistance (25, 26) . Our studies reveal that PPAR␥ activated adipocytes display enhanced responsiveness to insulin, and exert potent repressive functions on macrophage activation. These multiple mechanisms are not mutually exclusive. For instance, some adipokines and lipids can work as anti-inflammatory mediators, and their release may depend on the insulin signaling state of adipocytes. There are several advantages to the transgenic strategy used in this study. First, the PPAR␥ transgene allows us to study receptorspecific functions in absence of ligands such as TZDs which are known to harbor receptor-independent activities (27) . Second, since we made use of the aP2 promoter to drive adipose-specific expression, this results in expression of the transgene in mature adipocytes, but not in preadipocytes, as aP2 is expressed after adipogenesis has been initiated. Stimulation of adipogenesis by TZDs results in the complication of weight gain, yet can be beneficial by enabling fat to store more lipids and lower circulating free fatty acids (5). However, previously it has not been possible to determine whether insulin-sensitizing effects of TZD depend on adipogenesis per se (28) . Our data argue that PPAR␥ activation in mature adipocytes, but not in preadipocytes, is sufficient to dramatically improve insulin sensitivity without increased adipogenesis. This provides direct genetic support to the observations that several selective PPAR␥ modulators (SPARMs) can improve insulin sensitivity without causing weight gain (29) . This may reflect an ability of these compounds to regulate receptor activity more selectively in mature adipocytes, possibly through differential corepressor dismissal and coactivator recruitment.
Although TZDs are often referred to as ''insulin sensitizers,'' little evidence has been presented as to how PPAR␥ increases the ability of target cells to sense insulin. We identify several insulin signaling components including IRS-1 and GLUT4 as being upregulated in TZD-treated and TG mice. Another central regulator of insulin signaling, Akt, is highly activated by insulin in PPAR␥-activated adipose tissue. Reduction of insulin-signaling activities in adipocytes is associated with systemic insulin resistant states (30, 31) . This suggests that activation of adipocytic insulin signaling pathway observed following systemic TZD treatment or adipocyte The most potent ligand for expression changes per tissue is bold. A, AG035029; P, pioglitazone; R, rosiglitazone; T, troglitazone. *Significant by ANOVA, P Ͻ 0.05. † Significant difference between ligands in Tukey's post-hoc test, P Ͻ 0.05.
PPAR␥ activation is a bona fide indicator of improved insulin sensitivity in the whole body.
In addition, the finding that a number of immune response or inflammatory genes were found to be down-regulated in WAT can explain further mechanisms of insulin sensitization. We demonstrate that adipocytic PPAR␥ activation acts to limit the inflammatory response in this tissue. This suppression may be secondary to the induction of repressors such as NCoR. Recent studies demonstrated that macrophage PPAR␥ plays an important role in whole body insulin sensitization and glucose homeostasis (11, 12) . It was reported that aP2 is expressed in the macrophage and its expression enhanced by cell activation (21) . Our studies find that resident macrophages from WAT exhibited very limited expression of the transgene and PPAR␥/aP2 compared to adipocytes. Furthermore, a separate model of macrophage-selective PPAR␥ activation failed to improve diet-induced insulin resistance. Thus, while we do not exclude the possibility that macrophages per se play a role in systemic insulin sensitization, macrophage PPAR␥ is not reasonably expected to be a major contributor to the phenotype observed in our adipose-selective mouse model. Recently, it was reported that an increase of CXCL5, a member of C-X-C family chemokines, in adipose resident macrophages is correlated with obesity-associated insulin resistance (32). While we did not find involvement of CXCL5 in our models, other members of the family including CXCL2, CXCL10, and CXCL16 are significantly suppressed by adipocytic PPAR␥ activation. These data indicate that adipocytes themselves possess anti-inflammatory functions and modulate macrophage infiltration and activities, which may otherwise exacerbate the insulin resistant state.
In conclusion, we demonstrate that adipose-specific activation of PPAR␥ is sufficient for reversing whole body insulin resistance to a similar degree as systemic TZD treatment. Supporting this notion is that the non-TZD agonist AG035029, which has the greatest adipose specificity, exhibits the most potent insulin sensitizing activities. Recent concerns over adverse side effects by rosiglitazone, one of the two TZDs in the market, reveal that we do not fully understand how this drug works (33) . Our results suggest that it may be possible to dissociate the benefits from the complications and newer classes of PPAR␥ ligands that are insulin-sensitizing and nonadipogenic may preserve efficacy while lowering risk of side effects.
Materials and Methods
TG animals were generated by placing VP16-PPAR␥ downstream of the aP2 promoter and upstream of the SV40 poly(A) sequence. Founders were identified by PCR and Southern blotting (Fig. S1D) , then backcrossed to C57BL/6J animals for more than four generations. mTG animals were generated by placing the VP16-PPAR␥ transgene downstream of the human CD68 promoter (22) and betaglobin intron, and upstream of woodchuck posttranscriptional regulatory element (WPRE) and SV40 poly(A). The transgene was injected into an inbred C57BL/6J strain. Control animals that only express the VP16 domain were also generated and were phenotypically identical to wild-type (34) . For DNA microarray analysis, RNA was pooled from six mice or from two rats in each group. Samples from each group were labeled and hybridized to Affymetrix Mouse Genome 430 2.0 (n ϭ 2 each group) or Rat 230A (n ϭ 3 each) arrays. Functional annotations such as gene ontology (GO) were made using the VAMPIRE Microarray Analysis suite or DAVID Bioinformatics Resources. qPCR analyses using SYBR Green dye (Invitrogen) were run in triplicate and expression was normalized to the levels of the housekeeping control GAPDH. For phosphorylation assays, tissues intraportally infused with Humulin at 0.5 units/kg for 5 min were homogenized and their protein extracts were analyzed for phosphorylation levels of Akt using Bio-Plex Phosphoprotein Detection kits (Bio-Rad). In vitro transfection assay, metabolic measurements, histology, separation of different adipose cell types, and co-culture studies are described in SI Text. Unless noted, statistical comparisons were made using Student's t test. Error bars of the graphs are presented as mean Ϯ SEM. To identify genes differentially regulated by various PPAR␥ ligands, ANOVA was conducted on muscle, liver and adipose tissue microarray expression data from Zucker fatty rats treated for 21 days with AG035029 (24), pioglitazone, rosiglitazone, or troglitazone. Tukey's post-hoc tests were conducted to determine significant gene expression differences between pairs of treatment groups. Significance was evaluated after ANOVA and Tukey analyses using a cutoff P value of 0.05.
For more details, see SI Text.
